SRR13311160
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- OXIDATIVE_PHOSPHORYLATION+0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.490
- INTERFERON_GAMMA_RESPONSE+0.480
- DNA_REPAIR+0.370
- MYC_TARGETS_V1+0.320
- P53_PATHWAY+0.280
- ADIPOGENESIS+0.270
- MYC_TARGETS_V2+0.240
- PEROXISOME+0.210
Top 10 suppressed
- G2M_CHECKPOINT-0.440
- E2F_TARGETS-0.410
- SPERMATOGENESIS-0.330
- HEDGEHOG_SIGNALING-0.310
- MITOTIC_SPINDLE-0.280
- PANCREAS_BETA_CELLS-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- KRAS_SIGNALING_DN-0.170
- UV_RESPONSE_DN-0.160
- TNFA_SIGNALING_VIA_NFKB-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168542 | — | — | 0.872 |
| 2 | 022275BA-F672-49C5-887B-CCF24A20848F | — | — | 0.777 |
| 3 | C9C70D33-C09B-4F7E-8F12-FDE51817038A | — | — | 0.774 |
| 4 | DRR168518 | — | — | 0.750 |
| 5 | DRR168515 | — | — | 0.750 |
| 6 | DRR168511 | — | — | 0.744 |
| 7 | 82968 | EPN | Supratentorial EPN | 0.742 |
| 8 | DRR168579 | — | — | 0.715 |
| 9 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.702 |
| 10 | 7C6AF8DD-EFA4-4AD7-8AAC-918D686D78BA | — | — | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |